Oncology/Cancer Drugs Market by Drug Class Type (Chemotherapy, Targeted Therapy, Immunotherapy, and Hormonal Therapy) and Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2027
- ALL4621446
- 242 Pages
- March 2021
- Medical Devices
Cancer is the uncontrolled growth of abnormal cells in the body. Cancer develops when the body’s normal control mechanism stops working. Old cells do not die and instead grow out of control, forming new, abnormal cells. The treatment of cancer in patients requires the use of different drugs like hormonal therapy, immunotherapy, targeted therapy, and chemotherapy.
Biological drugs based on monoclonal antibodies (mAbs) have emerged as a preferred option to treat various cancer types. Rise in incidence of various cancer conditions, increase in popularity of advance therapies (biological and targeted drug therapies), and surge in geriatric population worldwide are the key factors driving the growth of the global oncology/cancer drugs market. Furthermore, rise in cancer awareness, early screening of the cancer and availability of cancer drugs are expected to boost the market growth.
However, high cost involved in new drug development coupled with threat of failure & adverse effects associated with cancer drugs therapies is expected to restrain the growth of the market. Conversely, high potential of emerging economies and higher number of potential drugs in pipeline are expected to provide new opportunities for market players in future.
The global oncology/cancer drugs market is segmented based on drug class type, indication, and region. Depending on drug class type, the market is divided into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. By indication, it is categorized into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers. Region wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global oncology/cancer drugs market along with the current trends and future estimations to elucidate the imminent investment pockets.
The report provides a quantitative analysis for the period of 2019–2027 to enable stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the market by components helps to understand the various types of instruments used across geographies.
Comprehensive analysis of all geographic regions is provided to determine the prevailing opportunities in these regions.
Key market players have been profiled in the report and their strategies have been analyzed thoroughly to understand the competitive outlook of the global market.
Extensive analysis of the market is conducted by closely following key product positioning, and monitoring the top contenders within the market framework.
KEY MARKET SEGMENTS
By Drug Class Type
• Chemotherapy
• Targeted Therapy
• Immunotherapy (Biologic Therapy)
• Hormonal Therapy
By Indication
• Lung Cancer
• Stomach Cancer
• Colorectal Cancer
• Breast Cancer
• Prostate Cancer
• Liver Cancer
• Esophagus Cancer
• Cervical Cancer
• Kidney Cancer
• Bladder Cancer
• Other Cancers
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Australia
o Japan
o India
o China
o Rest of Asia-Pacific
o
• LAMEA
o Latin America
o Middle East and Africa
o
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
1.4.4.Primary research
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies, 2019
3.3.Top player positioning, 2019
3.4.Porter’s five forces analysis
3.5.Clinical trials
3.6.Market dynamics
3.6.1.Drivers
3.6.1.1.Rise in incidence of cancer across the globe
3.6.1.2.Surge in global geriatric population
3.6.1.3.Increase in government expenditure on healthcare
3.6.2.Restraints
3.6.2.1.Adverse effects associated with the use cancer drugs
3.6.3.Opportunities
3.6.3.1.High growth potential in untapped emerging economies
3.6.3.2.Increase in number of pipeline drugs
3.6.4.Impact analysis
3.7.COVID-19 impact analysis on oncology/ cancer drugs market
CHAPTER 4:ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Chemotherapy
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Targeted therapy
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Immunotherapy (biologic therapy)
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Hormonal therapy
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
CHAPTER 5:ONCOLOGY/ONCOLOGY/CANCER DRUGS MARKET, BY INDICATIION
5.1.Overview
5.1.1.Market size and forecast
5.2.Lung cancer
5.2.1.Market size and forecast, by region
5.2.2.Market share analysis, by country
5.3.Stomach cancer
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Colorectal cancer
5.4.1.Market size and forecast, by region
5.4.2.Market share analysis, by country
5.5.Breast cancer
5.5.1.Market size and forecast, by region
5.5.2.Market share analysis, by country
5.6.Prostate cancer
5.6.1.Market size and forecast, by region
5.6.2.Market share analysis, by country
5.7.Liver cancer
5.7.1.Market size and forecast, by region
5.7.2.Market share analysis, by country
5.8.Esophagus cancer
5.8.1.Market size and forecast, by region
5.8.2.Market share analysis, by country
5.9.Cervical cancer
5.9.1.Market size and forecast, by region
5.9.2.Market share analysis, by country
5.10.Kidney cancer
5.10.1.Market size and forecast, by region
5.10.2.Market share analysis, by country
5.11.Bladder cancer
5.11.1.Market size and forecast, by region
5.11.2.Market share analysis, by country
5.12.Other cancers
5.12.1.Market size and forecast, by region
5.12.2.Market share analysis, by country
CHAPTER 6:ONCOLOGY/CANCER DRUGS MARKET, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.Market size and forecast, by country
6.2.2.1.U.S.
6.2.2.1.1.U.S. Oncology/Cancer Drugs Market, by drug class type
6.2.2.1.2.U.S. oncology/Cancer Drugs Market, by indication
6.2.2.2.Canada
6.2.2.2.1.Canada oncology/cancer drugs market, by drug class type
6.2.2.2.2.Canada oncology/cancer drugs market, by indication
6.2.2.3.Mexico
6.2.2.3.1.Mexico oncology/cancer drugs market, by drug class type
6.2.2.3.2.Mexico Oncology/Cancer Drugs Market, by indication
6.2.3.Market size and forecast, by drug class type
6.2.4.Market size and forecast, by indication
6.3.Europe
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Market size and forecast, by country
6.3.2.1.Germany
6.3.2.1.1.Germany oncology/cancer drugs market, by drug class type
6.3.2.1.2.Germany oncology/cancer drugs market, by indication
6.3.2.2.France
6.3.2.2.1.France oncology/cancer drugs market, by drug class type
6.3.2.2.2.France oncology/cancer drugs market, by indication
6.3.2.3.UK
6.3.2.3.1.UK oncology/cancer drugs market, by drug class type
6.3.2.3.2.UK oncology/cancer drugs market, by indication
6.3.2.4.Italy
6.3.2.4.1.Italy oncology/cancer drugs market, by drug class type
6.3.2.4.2.Italy oncology/cancer drugs market, by indication
6.3.2.5.Spain
6.3.2.5.1.Spain oncology/cancer drugs market, by drug class type
6.3.2.5.2.Spain oncology/cancer drugs market, by indication
6.3.2.6.Rest of Europe
6.3.2.6.1.Rest of Europe oncology/cancer drugs market, by drug class type
6.3.2.6.2.Rest of Europe oncology/cancer drugs market, by indication
6.3.3.Market size and forecast, by drug class type
6.3.4.Market size and forecast, by indication
6.4.Asia-Pacific
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Market size and forecast, by country
6.4.2.1.Japan
6.4.2.1.1.Japan oncology/cancer drugs market, by drug class type
6.4.2.1.2.Japan oncology/cancer drugs market, by indication
6.4.2.2.China
6.4.2.2.1.China oncology/cancer drugs market, by drug class type
6.4.2.2.2.China oncology/cancer drugs market, by indication
6.4.2.3.Australia
6.4.2.3.1.Australia oncology/cancer drugs market, by drug class type
6.4.2.3.2.Australia oncology/cancer drugs market, by indication
6.4.2.4.India
6.4.2.4.1.India cancer oncology/cancer market, by drug class type
6.4.2.4.2.India oncology/cancer drugs market, by indication
6.4.2.5.South Korea
6.4.2.5.1.South Korea oncology/cancer drugs market, by drug class type
6.4.2.5.2.South Korea oncology/cancer drugs market, by indication
6.4.2.6.Rest of Asia-Pacific
6.4.2.6.1.Rest of Asia-Pacific oncology/cancer drugs market, by drug class type
6.4.2.6.2.Rest of Asia-Pacific oncology/cancer drugs market, by indication
6.4.3.Market size and forecast, by drug class type
6.4.4.Market size and forecast, by indication
6.5.LAMEA
6.5.1.Key market trends, growth factors, and opportunities
6.5.2.Market size and forecast, by country
6.5.2.1.Brazil
6.5.2.1.1.Brazil oncology/cancer drugs market, by drug class type
6.5.2.1.2.Brazil oncology/cancer drugs market, by indication
6.5.2.2.Saudi Arabia
6.5.2.2.1.Saudi Arabia oncology/cancer drugs market, by drug class type
6.5.2.2.2.Saudi Arabia oncology/cancer drugs market, by indication
6.5.2.3.South Africa
6.5.2.3.1.South Africa oncology/cancer drugs market, by drug class type
6.5.2.3.2.South Africa oncology/cancer drugs market, by indication
6.5.2.4.Rest of LAMEA
6.5.2.4.1.Rest of LAMEA oncology/cancer drugs market, by drug class type
6.5.2.4.2.Rest of LAMEA cancer drugs market, by indication
6.5.3.Market size and forecast, by drug class type
6.5.4.Market size and forecast, by indication
CHAPTER 7:COMPANY PROFILES
7.1.ABBVIE INC.
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.1.6.Key strategic moves and developments
7.2.AMGEN INC.
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance
7.2.6.Key strategic moves and developments
7.3.ASTELLAS PHARMA INC.
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product Portfolio
7.3.5.Business performance
7.4.ASTRAZENECA PLC.
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product Portfolio
7.4.5.Business performance
7.4.6.Key strategic moves and developments
7.5.BRISTOL-MYERS SQUIBB COMPANY
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product Portfolio
7.5.5.Business performance
7.5.6.Key strategic moves and developments
7.6.F. HOFFMANN-LA ROCHE LTD.
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance.
7.6.6.Key strategic moves and developments
7.7.JOHNSON & JOHNSON (JANSSEN GLOBAL SERVICES, LLC,)
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.8.MERCK & CO., INC.
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product Portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments
7.9.NOVARTIS INTERNATIONAL AG (SANDOZ)
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.9.6.Key strategic moves and developments
7.10.PFIZER INC.
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
TABLE 01.COMPLETED CLINICAL TRIALS IN CANCER DRUGS MARKET, 2017–2021
TABLE 02.ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027 ($MILLION)
TABLE 03.ONCOLOGY/CANCER DRUGS MARKET FOR CHEMOTHERAPY, BY REGION, 2019–2027 ($MILLION)
TABLE 04.ONCOLOGY/CANCER DRUGS MARKET FOR TARGETED THERAPY, BY REGION, 2019–2027 ($MILLION)
TABLE 05.ONCOLOGY/CANCER DRUGS MARKET FOR IMMUNOTHERAPY (BIOLOGIC THERAPY), BY REGION, 2019–2027 ($MILLION)
TABLE 06.ONCOLOGY/CANCER DRUGS MARKET FOR HORMONAL THERAPY, BY REGION, 2019–2027 ($MILLION)
TABLE 07.ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027($MILLION)
TABLE 08.ONCOLOGY/CANCER DRUGS MARKET FOR LUNG CANCER, BY REGION, 2019–2027($MILLION)
TABLE 09.ONCOLOGY/CANCER DRUGS MARKET FOR STOMACH CANCER, BY REGION, 2019–2027($MILLION)
TABLE 10.ONCOLOGY/CANCER DRUGS MARKET FOR COLORECTAL CANCER, BY REGION, 2019–2027($MILLION)
TABLE 11.ONCOLOGY/CANCER DRUGS MARKET FOR BREAST CANCER, BY REGION, 2019–2027($MILLION)
TABLE 12.ONCOLOGY/CANCER DRUGS MARKET FOR PROSTATE CANCER, BY REGION, 2019–2027($MILLION)
TABLE 13.ONCOLOGY/CANCER DRUGS MARKET FOR LIVER CANCER, BY REGION, 2019–2027($MILLION)
TABLE 14.ONCOLOGY/CANCER DRUGS MARKET FOR ESOPHAGUS CANCER, BY REGION, 2019–2027($MILLION)
TABLE 15.ONCOLOGY/CANCER DRUGS MARKET FOR CERVICAL CANCER, BY REGION, 2019–2027($MILLION)
TABLE 16.ONCOLOGY/CANCER DRUGS MARKET FOR KIDNEY CANCER, BY REGION, 2019–2027($MILLION)
TABLE 17.ONCOLOGY/CANCER DRUGS MARKET FOR BLADDER CANCER, BY REGION, 2019–2027($MILLION)
TABLE 18.ONCOLOGY/CANCER DRUGS MARKET FOR OTHER CANCERS, BY REGION, 2019–2027 ($MILLION)
TABLE 19.ONCOLOGY/CANCER DRUGS MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)
TABLE 20.NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 21.U.S. ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 22.U.S. ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 23.CANADA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 24.CANADA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 25.MEXICO ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 26.MEXICO ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 27.NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027 ($MILLION)
TABLE 28.NORTH AMERICA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 29.EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 30.GERMANY ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 31.GERMANY ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 32.FRANCE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 33.FRANCE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 34.UK ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 35.UK ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 36.ITALY ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 37.ITALY ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 38.SPAIN ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 39.SPAIN ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 40.REST OF EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 41.REST OF EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 42.EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027 ($MILLION)
TABLE 43.EUROPE ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 44.ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 45.JAPAN ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 46.JAPAN ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 47.CHINA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 48.CHINA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 49.AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 50.AUSTRALIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 51.INDIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 52.INDIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 53.SOUTH KOREA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 54.SOUTH KOREA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 55.REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 56.REST OF ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 57.ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027 ($MILLION)
TABLE 58.ASIA-PACIFIC ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 59.LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 60.BRAZIL ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 61.BRAZIL ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 62.SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 63.SAUDI ARABIA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 64.SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 65.SOUTH AFRICA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 66.REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027
TABLE 67.REST OF LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027
TABLE 68.LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY DRUG CLASS TYPE, 2019–2027 ($MILLION)
TABLE 69.LAMEA ONCOLOGY/CANCER DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 70.ABBVIE: COMPANY SNAPSHOT
TABLE 71.ABBVIE: OPERATING SEGMENT
TABLE 72.ABBVIE: PRODUCT PORTFOLIO
TABLE 73.ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 74.AMGEN: COMPANY SNAPSHOT
TABLE 75.AMGEN: OPERATING SEGMENT
TABLE 76.AMGEN: PRODUCT PORTFOLIO
TABLE 77.ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 78.ASTELLAS: COMPANY SNAPSHOT
TABLE 79.ASTELLAS: PRODUCT PORTFOLIO
TABLE 80.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 81.ASTRAZENECA: OPERATING SEGMENTS
TABLE 82.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 83.BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
TABLE 84.BRISTOL-MYERS SQUIBB: PRODUCT PORTFOLIO
TABLE 85.ROCHE: COMPANY SNAPSHOT
TABLE 86.ROCHE: OPERATING SEGMENTS
TABLE 87.ROCHE: PRODUCT PORTFOLIO
TABLE 88.J&J: COMPANY SNAPSHOT
TABLE 89.J&J: OPERATING SEGMENTS
TABLE 90.J&J: PRODUCT TYPE PORTFOLIO
TABLE 91.MERCK: COMPANY SNAPSHOT
TABLE 92.MERCK: OPERATING SEGMENTS
TABLE 93.MERCK: PRODUCT PORTFOLIO
TABLE 94.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 95.NOVARTIS: OPERATING SEGMENTS
TABLE 96.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 97.PFIZER: COMPANY SNAPSHOT
TABLE 98.PFIZER: OPERATING SEGMENTS
TABLE 99.PFIZER: PRODUCT PORTFOLIO
Similar Reports
Medical implants are permanent devices such as pacemakers or temporary devices such as fracture plates which are removed once their function is completed. These implants are made up of bone, tissue, skin, ceramics, metals, plastics, and other natural materials...
- Publish Date: August 21, 2016
- $5370
Ostomy is a surgery wherein an artificial opening, known as stoma, is created from the colon in the human body to eliminate body wastes such as urine, mucus, and stools, which are collected in artificial bags called ostomy drainage bags. These plastic/rub...
- Publish Date: December 1, 2016
- $5370
Laparoscopy is a minimally invasive procedure used to examine organs inside the abdomen or pelvic cavities by inserting a laparoscope through a small incision in the abdomen. A laparoscope comprises a long, thin tube with high-intensity light, and high-re...
- Publish Date: April 24, 2017
- $5370
